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STOP MONKEYING AROUND WITH HUMAN HEALTH:
MOVING HUMAN DRUG DEVELOPMENT INTO THE
21ST CENTURY BY ABANDONING ANIMAL MODELS,
VALIDATING EMERGING TEST METHODS,
UPDATING FDA REGULATIONS, AND
ISSUING FDA GUIDANCE
Elizabeth Baker*
“A major problem in the pharmaceutical industry right now is that
the drug development model is actually broken. It just does not
work. It takes many, many years to get a drug to market, it’s incredibly expensive, innumerable animal lives are lost – and then
the results from animals usually don’t predict what happens in
humans.”1

Introduction
The Stark Statistics
Ninety-two percent of all drugs found safe in animal tests fail
during human clinical trials due to their toxicity and/or inefficacy.2
Of the eight percent of drugs that do gain Food and Drug Administration (FDA) approval, over half are later withdrawn or relabeled due
to severe, unexpected side effects.3 Moreover, adverse drug reactions
to prescription drugs are the fourth leading cause of death in the
United States.4 Drug development is stuck in an innovation gap as
research and development funds substantially increase without an increase in approved drugs.5
* Elizabeth Baker is a Juris Doctorate Candidate, May 2014, at California
Western School of Law.
1. Don Ingber, Building an Organ on a Chip, MIT TECHNOLOGY REVIEW,
July/August 2012, http://www.technologyreview.com/demo/427992/building-anorgan-on-a-chip/ (last visited May 3, 2013).
2. U.S. FOOD AND DRUG ADMIN., INNOVATION OR STAGNATION: CHALLENGE
AND OPPORTUNITY ON THE CRITICAL PATH TO NEW MEDICAL PRODUCTS 8 (2004).
3. FDA Drug Review: Postapproval Risks 1976-1985 at 3, U.S. General
Accounting Office (1990), available at http://www.gao.gov/assets/150/149086.pdf.
4. Jason Lazarou, et al., Incidence of Adverse Drug Reactions in Hospital
Patients, 279 JAMA 1200, 1200 (1998).
5. H. Geerts, Of Mice and Men: Bridging the Translational Disconnect of
CNS in Drug Discovery, 23 CNS DRUGS 915, 915 (2009).
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The Need for Change
Despite rapidly developing technologies and emerging science,
the drug development paradigm has changed little since its 1960s inception.6 The combination of the complexities of assessing successful
drug compounds, rising drug development costs and high clinical
failure rates, have resulted in a need for re-evaluation of the current
drug development paradigm.7 The Food and Drug Administration
(FDA) acknowledged the drug development innovation gap in a 2004
report, and highlighted the urgent need for a better drug development
toolkit.8
Animal Models are Deficient
The current drug development paradigm relies on in vitro testing
and in vivo animal models to screen which drugs should continue the
development process and be tested in humans.9 Data from animal
models is a problematic screening tool for human drugs because it
often cannot be transposed to human clinical testing,10 and most
animal-based testing methods have never been scientifically
validated.
The premise that animal models are generally predictive of
human outcomes is the basis for their widespread use in safety and
efficacy testing during human drug development.11 However, the
FDA repeatedly acknowledges reliance on animal models is deficient
and results in high clinical failure rates.12 Further, the use of animal
6. Shivaani Kummar, et al., Phase 0 Clinical Trials: Recommendations from
the Task Force on Methodology for the Development of Innovative Cancer
Therapies, 45 EUR J CANCER 741, 742 (2009).
7. Id.
8. See U.S. Food and Drug Admin, supra note 2, at 11.
9. Paolo Preziosi, Science, Pharmacoeconomics and Ethics in Drug R&D: A
Sustainable Future Scenario?, 3 NATURE REVIEWS DRUG DISCOVERY 521, 522
(2004).
10. Michael Spedding, et al., A Pathophysiological Paradigm for the Therapy
of Psychiatric Disease, 4 NATURE REVIEWS DRUG DISCOVERY 467, 468 (2005).
11. ANDREW KNIGHT, THE COSTS AND BENEFITS OF ANIMAL EXPERIMENTS 41
(2011).
12. “Currently, nine out of ten experimental drugs fail in clinical studies
because we cannot accurately predict how they will behave in people based on
laboratory and animal studies.” News Release, FDA, FDA Issues Advice to Make
Earliest Stages of Clinical Drug Development More Efficient (Jan. 12, 2006) (on
file with the FDA); “Consider just one stark statistic: Today, nine out of 10
compounds developed in the lab fail in human studies. They fail, in large part
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models arguably adds unnecessary expense and delay to the drug development process.
The Need to Accept and Implement 21st Century Science and
Technology
The FDA recognizes creating scientific tools and processes necessary to bring drug development into the 21st Century is a monumental effort requiring collaboration of federal agencies, patient
groups, academic researchers, industry, healthcare practitioners, and
others.13 As the federal agency that oversees and regulates drug development,14 the FDA must take a spearheading role to initiate
change.
Although the FDA has stated its concern with reliance on animal
model data,15 and a need for a better drug development toolkit,16
FDA regulations still require animal data.17 The FDA is involved in
projects to move validation of emerging science forward,18 but until
FDA regulations that govern drug development are changed, or clear
FDA guidance documents that recommend use of non-animal testing
methods are issued, sponsors will continue to use the outdated research methods the FDA wants to change.

because they behave differently in people than they did in animal or laboratory
tests.” Prepared Statement for FDA Teleconference: Steps to Advance the Earliest
Phases of Clinical Research in the Development of Innovative Medical Treatments
(January 12, 2006) (on file with the FDA); “The main causes of failures before
human testing or early in clinical trials dramatically escalates costs. For example,
for a pharmaceutical, a 10-percent improvement in predicting failures before
clinical trials could save $100 million in development costs per drug.” U.S Food
and Drug Admin., supra note 2, at 8.
13. FDA’s Critical Path Initiative, http://www.fda.gov/ScienceResearch/
SpecialTopics/CriticalPathInitiative/ucm076689.htm (last visited May 3, 2013).
14. 21 U.S.C.A § 393 (West 2011).
15. Donald Prater, U.S. Food and Drug Admin. Powerpoint Presentation,
Development and use of Advancing Testing Approaches by the U.S. FDA,
Presented at “Advancing Safety Science and Health Research Under Horizon 2020
with Innovative, Non-Animal Tools” (Oct. 10, 2012) (on file with FDA).
16. U.S. Food and Drug Admin, supra note 2, at 8.
17. 21 C.F.R § 312.23(a)5(ii) (West 2012), 21 C.F.R § 312.23(a)(5)(iii) (West
2012), 21 C.F.R. 312.23(8)(i) (West 2012), 21 C.F.R. § 312.23(8)(ii)(a) (West
2012), 21. C.F.R. § 312.23 (10)(i) (West 2012).
18. See infra Part III.
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Although the FDA accepts data from certain non-animal models
which have passed the formal validation process,19 animal models
remain the regulated testing method of nonclinical safety assessment
of pharmacology studies, general toxicity studies, toxicokinetic and
pharmacokinetic studies, reproduction toxicity studies, nontoxicity
studies and carcinogenicity studies, and this animal data must be provided regardless of whether the alternative method was validated.20
These regulations may stifle development and use of emerging science because even when drug sponsors use emerging science to test
drugs, they still use time and money to gather the required animal
data, which may contradict the emerging science data.
Road Map
This paper discusses reliance on the animal model as a problematic component of the current drug development paradigm, and the
need for further FDA action to bring drug development into the 21st
Century. Part one of this paper describes a brief history of animal
models in drug development, outlines the current drug development
paradigm, and then explains drug development problems stemming
from the animal model. Part two summarizes current law and policy
governing drug development. Part three identifies emerging drug development test methods, summarizes FDA efforts to develop and validate more reliable test methods, and offers recommendations for further FDA action to allow drug development to transition into the 21st
Century. This paper will not discuss ethical implications of using
animal models in human drug development.

Part 1: History of Animal Models in
Drug Development
The use of animal models for scientific research has been accepted as an appropriate research tool since the 2nd Century, when
Galen became the father of animal testing.21 The modern version of
19. Response from David Dorsey, J.D., Associate Commissioner for Policy
and Planning, to Citizen Petition Docket No. FDA-2007-P-0109, (formerly Docket
No. 2007P-0457) (May 20, 2010) (on file with Federal Registrar).
20. Int’l Conference on Harmonization, Guidance for Industry: M3
Nonclinical Safety Studies for the Conduct of Human Clinical Trials for
Pharmaceuticals (July 1997).
21. C. RAY GREEK & JEAN SWINGLE GREEK, SACRED COWS AND GOLDEN
GEESE: THE HUMAN COST OF EXPERIMENTS ON ANIMALS, 23 (2000).
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animal testing began in the 19th century with Claude Bernard who
believed organs and tissues were interchangeable among animals, and
differences could be accounted for by scaling.22 However, animal
testing was not a required part of drug development until the 20th
century.23
In 1938, Congress enacted the United States Federal Food, Drug
and Cosmetic Act (FDCA), marking the first attempt to regulate drug
safety because the FDCA required passive FDA approval based on a
showing the drug was safe for its intended purpose.24The FDCA was
a reaction to mass poisoning and over 100 deaths related to use of a
sulphanilamide elixir containing diethylene glycol.25 Scientists administered the elixir to animals, which also died.26 This occasion of
parity convinced the scientific community that animals should be
used for testing all medications.27
Nearly two decades after passing the FDCA, doctors prescribed
thalidomide to pregnant women for relief of morning sickness symptoms without knowledge that thalidomide caused birth defects.28
Consequently, over 10,000 people from various countries were born
missing limbs or deformed.29 After three years of congressional hearings, Congress approved the 1962 Kefauver-Harris Amendments to
the FDCA, which added an efficacy requirement.30 The FDCA now
required the FDA to review drug safety and efficacy data before
granting drug approval.31 Through FDA mandates, animal testing became the gold standard for testing drug safety and efficacy.32
The Current Drug Development Paradigm
The Center for Drug Evaluation and Research (CDER) is the
division of the U.S. FDA charged with ensuring drugs are both safe
22. Ray Greek, Animal Models in Drug Development, in NEW INSIGHTS INTO
TOXICITY AND DRUG TESTING 124, (Sivakumar Gowder ed., 2013).
23. Rachel Hajar, Animal Testing and Medicine, 12 HEART VIEWS 42 (2011).
24. Preziosi, supra note 9, at 521.
25. Id.
26. C. RAY GREEK, supra note 21, at 43
27. Id.
28. Hajar, supra note 23, at 42.
29. Id.
30. Food Drug Cosm. L. Rep. (CCH), Pub. L. No. 87-781, 76 Stat. 1552
(1962).
31. Preziosi, supra note 9, at 521.
32. C. RAY GREEK, supra note 21, at 48.
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and effective for their intended use.33 CDER will only approve a drug
after a sponsor has demonstrated the drug is safe and effective.34 In
order to meet these criteria, drug sponsors follow a step-by-step testing process, providing evidence to the FDA throughout the process.35
Drug development starts with the discovery phase where developers 1) determine a target disease, 2) determine each component of
the disease including symptoms, 3) identify the target organ, and biochemical pathways, 4) search for the target drug, and 5) isolate the
compound.36 The challenge is to select and advance a small number
of compounds that contain properties that will eventually predict
safety and efficacy in humans.37
After a compound is selected during the discovery phase, investigators begin preclinical testing which includes testing compounds in
vitro, then in vivo in laboratory animals.38 During preclinical stages
of drug development, investigators conduct multiple types of studies.
Pharmacological studies vary in nature depending upon the type of
drug being developed.39 Researchers also conduct secondary pharmacological studies to assess drug safety by testing on major organs and
organ systems.40 Pharmacokinetic studies evaluate absorption, distribution, metabolism and excretion of the drug.41Finally, investigators
conduct toxicological testing in an attempt to predict adverse effects
in humans that might be triggered by the drug.42
If investigators decide the preclinical data indicates the drug is
reasonably safe for initial use in humans, the drug developer submits
33. About the Center for Drug Evaluation and Research, http://www.fda.gov/
AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/default.
htm (last visited May 5, 2013).
34. The FDA’s Drug Review Process: Ensuring Drugs are Safe and Effective,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm (last visited
May 2, 2013).
35. Id.
36. Drug Development Process: Stages of Drug Development, http://www.
pacificbiolabs.com/drug_stages.asp (last visited May 2, 2013).
37. J. Fred Pritchard, Making Better Drugs: Decision Gates in Non-Clinical
Drug Development, 2 NATURE REVIEWS DRUG DISCOVERY 542, 542 (2003).
38. Michael Dickson, Key Factors in the Rising Cost of New Discovery and
Development, 3 NATURE REVIEWS DRUG DISCOVERY 417, 418 (2004).
39. Preziosi, supra note 9, at 521.
40. Id., at 521-22.
41. Id.
42. Id.

\\jciprod01\productn\N\NCP\7-1\ncp112.txt

2014]

unknown

Seq: 7

15-MAY-14

STOP MONKEYING AROUND WITH HUMAN HEALTH

12:18

95

an investigational new drug application (IND) to the FDA.43 The IND
includes a description of the compound’s pharmacological profile, results of short-term toxicity testing in at least two animal species,
manufacturing information, and proposed clinical protocols and investigator information.44 If the FDA is satisfied that the drug is reasonably safe for human use, and a local institutional review board
approves the clinical trial protocols, investigators begin human
clinical testing.45When the compound enters human clinical trials, investigators conduct additional concurrent toxicology studies on animals for the duration of clinical trials.46 In addition, carcinogenicity
studies continue for approximately two years, to examine whether the
drug is carcinogenic if given for the lifetime of the animal.47
Human clinical trials are broken up into three phases.48 Investigators conduct Phase 1 clinical trials in twenty to eighty healthy volunteers49 to determine safe dosing and toxicity.50 If Phase 1 trials do
not reveal unacceptable toxicity, the drug candidate moves to Phase 2
studies.51 Investigators conduct Phase 2 clinical trials in a few dozen
to 300 patient volunteers who have the medical condition to determine whether the drug works in people who have the condition the
drug is intended to treat.52 The drug moves to Phase 3 trials if Phase 2
trials show evidence of efficacy.53 Phase 3 clinical trials are con43. Investigational New Drug Application, http://www.fda.gov/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approval
Applications/InvestigationalNewDrugINDApplication/default.htm (last visited
May 2, 2013).
44. Id.
45. The FDA’s Drug Review Process: Ensuring Drugs are Safe and Effective,
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.htm (last
visited May 2, 2013).
46. Pritchard, supra, at 551.
47. Id.
48. The FDA’s Drug Review Process : Ensuring Drugs are Safe and
Effective, http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.
htm (last visited May 2, 2013).
49. Id.
50. Dickson, supra note 38, at 418.
51. The FDA’s Drug Review Process : Ensuring Drugs are Safe and
Effective, http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.
htm (last visited May 2, 2013).
52. Id.
53. Id.
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ducted for safety and efficacy in groups of several hundred to 3000
patient volunteers.54
After completing human clinical tests, the sponsor files a new
drug application (NDA), seeking formal FDA approval of the drug
for sale and marketing in the United States.55 The NDA includes data
gathered during animal and human testing, analyses of the data, information on how the drug behaves in the body from clinical studies,
and manufacturing information.56 Within sixty days, the FDA decides
whether to file the NDA so it can be reviewed, or refuse to file the
NDA.57 If, after NDA review, the FDA decides the known benefits of
the drug outweigh the known risks, the FDA approves the drug and
the drug can be marketed in the United States.58
Drug Development Problems Related to Animal Models
Scientists test their ideas by comparing predictions based on theory to actual events in nature or the laboratory.59 If a method gets the
right answer often enough, it can be said to be predictive. In contrast,
if a method does not get the right answer often enough, it cannot be
said to be predictive.
The purpose of preclinical testing is to predict human outcomes.60 Investigators gather animal data and extrapolate to form hypotheses regarding what is likely to occur when humans receive the
drug.61 The rationale behind extrapolating results from animals to
humans is based on homology and evolutionary similarity between
morphological structures and physiological processes between ani54. Id.
55. New Drug Application, http://www.fda.gov/Drugs/DevelopmentApproval
Process/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrug
ApplicationNDA/default.htm (last visited May 2, 2013).
56. The FDA’s Drug Review Process : Ensuring Drugs are Safe and
Effective, http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.
htm (last visited May 2, 2013).
57. Id.
58. Id.
59. Daniel Sarewitz & Roger Pielke, Prediction in Science and Policy, 21
TECHNOLOGY IN SOCIETY 121, 123 (1999).
60. Ray Greek, supra note 22, at 127.
61. Niall Shanks, Ray Greek, Jean Greek, Are Animal Models Predictive for
Humans? 4 PHILOSOPHY, ETHICS, AND HUMANITIES IN MEDICINE, http://www.pehmed.com/content/pdf/1747-5341-4-2.pdf (last visited May 3, 2013).
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mals and humans.62 However, among other things, species differ in
gene presence, gene mutation, number of alleles, gene expression,
gene networks, and convergent evolution.63
Inter-species differences in pharmacodynamics and
pharmacokinetics result in extrapolation issues.64 According to the
FDA, the inability to assess and predict product safety leads to failures during clinical development.65To further highlight the extrapolation disparity, the FDA uses the statistic that ninety-two percent of
drugs that pass preclinical animal testing later fail during human
clinical trials.66 In studying adverse reactions, one study found only
forty-six percent of visible human adverse reactions occurred in animals, making the predictive likelihood of adverse reactions akin to
the results of a coin toss.67
Furthermore, a 2012 study looked at whether post-marketing serious adverse reactions to small molecule drugs could have been detected from animal data.68 Animal data identified only nineteen percent of human adverse reactions, leading researchers to conclude
animal data is not relevant to predict serious adverse human reactions
to new small molecule drugs.69
Extrapolating data misleads research because animal experiments may fail to predict lethal side effects and prevent or delay safe
and effective medications from gaining FDA approval.70 Animal testing that wrongly makes a candidate drug appear safe for humans is
called a false negative.71 As a result of false negatives, adverse drug
reactions are the fourth leading cause of death in the United States,
accounting for approximately 100,000 deaths per year.72 There is a
long list of drugs that were given to humans after the drug appeared
62. Jann Hau, & Geral L. Van Hoosier, Animal Models, 2 Handbook of
Laboratory Animal Science 1, 6 (Hau, et al. 2003).
63. Ray Greek, supra note 22, at 126.
64. KNIGHT, supra note 11, at 92.
65. U.S. Food and Drug Admin., supra note 2, at 17.
66. Id. at 8.
67. C. RAY GREEK, supra note 21, at 48.
68. Peter J.K. van Meer, Marlous Kooijman, Christine C. Gispen-de Wied,
Ellen H.M. Moors & Huub Schellkens, THE ABILITY OF ANIMAL STUDIES TO
DETECT SERIOUS POST MARKETING ADVERSE EVENTS IS LIMITED, 64 Regulatory
Toxicology and Pharmacology 345, 346 (2012).
69. Id.
70. C. RAY GREEK, supra note 21, at 60.
71. Id.
72. Id.
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safe in animal studies that resulted in severe adverse reactions and
death in many people.73 Scientists did not learn the drugs were dangerous to humans through animal testing; scientists learned the drugs
were dangerous to humans through epidemiology, clinical observation, and autopsy.74
In contrast, drugs that are safe and effective in humans, but
cause severe adverse reactions in animals that keep the candidate
drug from development are called false positives.75 To say animal
models keep good drugs from the market is difficult to prove because
the compound is not generally developed after faring negatively in
animals.76 However, occasionally drugs are approved for use in other
countries that are safe and effective in humans but are delayed in the
United States because the FDA requires either abbreviated animal
testing or the entire protocol.77
Scientists can judge the appropriateness of extrapolating data
from models by their capacity to explain and predict the observed
effects in the target species.78 Systematic reviews of research data
allow scientists to compare animal and human data to confirm or falsify the animal-based hypothesis.79 A 2007 comprehensive survey of
systematic reviews found that eighteen of twenty systematic reviews
published in peer-reviewed scientific journals suggest animals are insufficiently predictive of human clinical or toxicological outcomes.80
One explanation for the systematic review findings is that animal
models were never scientifically validated.81 Therefore, animal models are not held to the validation standards emerging testing methods
are held to.82

73.
74.
75.
76.
77.
78.
79.
80.
81.

Id. at 61-66.
Id. at 66.
Id. at 60.
Id. at 69.
Id. at 71.
Jann Hau, supra note 62, at 8.
KNIGHT, supra note 11, at 42.
KNIGHT, supra note 11, at 183.
Alison Abbott, Animal Testing: More than a Cosmetic Change, 438
NATURE 144, (2005).
82. Id.
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Part II: Current Law and Policy Governing
Drug Development
Food and Drug Administration
The FDA is partially tasked with ensuring human drugs are safe
and effective.83 By statute, the FDA has discretion whether to require
animal data.84 While the FDA says it will accept non-animal methods
provided they are equal to or better than the animal model,85 FDA
regulations require preclinical animal data to examine
pharmacokinetics and biological disposition of the drug, pharmacological mechanisms including absorption, distribution, metabolism,
and excretion, and a summary of toxicological effects.86 Further, the
FDA’s website explanation of drug development states the sponsor
must show the FDA results of preclinical testing in laboratory animals and what they propose to do for human testing.87
In addition to promulgating regulations, the FDA issues guidance documents to communicate expectations to drug developers.88
Although non-binding, FDA guidance documents often have a binding effect because failure to comply may result in disapproval of an
application.89 The FDA issues more guidance documents than regulations,90 but it has not issued any guidance that recommends the use of
non-animal testing models.91 In a 2010 citizen petition denial, the
FDA expressed intention to issue a clear guidance to industry and
FDA staff on use of adequate and validated non-animal testing methods.92 This guidance has not been issued and it is not included in the
2014 draft guidance agenda.93
83. 21 U.S.C.A § 393 (West 2011).
84. 21 U.S.C.A § 355 (West 2013).
85. Dorsey, supra note 19, at 3.
86. Investigational New Drug Application, 21 C.F.R. § 312.23 (2012).
87. The FDA’s Drug Review Process : Ensuring Drugs are Safe and
Effective, http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.
htm (last visited May 2, 2013).
88. Jessica Mantel, Procedural Safeguards for Agency Guidance: A Source of
Legitimacy for the Administrative State, 61 ADMIN. L. REV. 343, 353 (2009).
89. Id. at 351-52.
90. Id. at 353.
91. U.S. Food and Drug Admin., Regulatory Information: Guidances, http://
www.fda.gov/regulatoryinformation/guidances/ (last visited May 1, 2013).
92. Dorsey, supra note 19, at 2.
93. Guidance Agenda: New & Revised Draft Guidances CDER is Planning to
Publish During Calendar Year 2014, http://www.fda.gov/downloads/Drugs/
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Interagency Coordinating Committee on the Validation of
Alternative Methods
In 2000, Congress established the Interagency Coordinating
Committee on the Validation of Alternative Methods (ICCVAM).94
Part of ICCVAM’s purpose is to increase the efficiency and effectiveness of Federal agency test method review.95 However, the
ICCVAM process is recognized as an obstacle to test validation because the process is slow and expensive.96 Although the FDA is an
agency member of ICCVAM, the FDA retains final authority regarding whether to accept ICCVAM’s recommendations.97
International Cooperation on Alternative Test Methods
The International Cooperation on Alternative Test Methods
(ICATM) is collaboration between the United States, Europe, Japan,
and Canada.98 ICATM represents an effort to promote international
cooperation to accelerate regulatory acceptance of new testing
methods.99
International Conference on Harmonization
The International Conference on Harmonization (ICH) launched
in 1990 to improve efficiency and harmonize research guidelines in
the United States, Japan, and Europe.100 The ICH issues guidelines on
quality, safety, and efficacy.101 Multiple ICH guidelines recommend
testing a drug in animals to determine whether the drug is safe for
human clinical trials.102
GuidanceComplianceRegulatoryInformation/Guidances/UCM314767.pdf (last
visited April 6, 2014).
94. ICCVAM Authorization Act of 2000, Pub. L. No. 106-545, 114 Stat.
2721, 2721 (2000).
95. Id. at 2721-2722.
96. Gilbert M. Gaul, In U.S., Few Alternatives To Testing On Animals, WASH.
POST, April 12, 2008, http://www.washingtonpost.com/wp-dyn/content/article/
2008/04/11/AR2008041103733.html.
97. ICCVAM, supra note 93, at 2722-2725. 114 Stat. 2721 (2000).
98. International Cooperation on Alternative Test Methods, http://iccvam.
niehs.nih.gov/about/icatm.htm (last visited May 2, 2013).
99. Id.
100. ICH Harmonisation for Better Health, Vision, http://www.ich.org/about/
vision.html (last visited May 2, 2013).
101. ICH Harmonisation for Better Health, ICH Guidelines, http://www.ich.
org/products/guidelines.html (last visited May 2, 2013).
102. ICH Harmonisation for Better Health, Safety Guidelines, http://www.ich.
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Part III: Emerging Drug Development
Testing Methods
Although animal models are still regulated as a central part of
the drug development process, the FDA has approved certain nonanimal models for preclinical use. In addition, emerging science and
technologies that aim to provide improved predictions of human drug
safety with the objective of replacing the current preclinical paradigm
are in progress.103 Below are examples of emerging testing methods.
Human Organ-on-a-Chip System
The Wyss Institute for Biologically Inspired Engineering at
Harvard successfully created a lung-on-a-chip and gut-on-a-chip,
which mimic the mechanical and biochemical behaviors of corresponding human organs.104 In 2012, the Wyss Institute received funding to create ten human organs-on-a-chip, which will link together to
mimic whole body human physiology.105 The lung-on-a-chip seeks to
replace current preclinical animal models by offering a system that
rapidly assesses responses to new drug candidates, providing critical
information on their safety and efficacy.106
Human Pluripotent Stem Cell
Pluripotent stem cells give rise to almost all cell types of the
body making them beneficial for drug development research.107 Research using pluripotent stem cells may replace animal models for
evaluating drug safety because candidate drugs may be tested on cells
developed from human pluripotent stem cells.108 Researchers at The
org/products/guidelines/safety/article/safety-guidelines.html (last visited May 2,
2013).
103. C. Thomas Caskey, The Drug Development Crisis: Efficiency and
Safety, 58 ANN. REV MED. 1, 5 (2007).
104. Wyss Institute at Harvard, Lung-on-a-chip, http://wyss.harvard.edu/
viewpage/240/lungonachip (last visited May 2, 2013).
105. Wyss Institute, Wyss Institute to Receive up to $37 Million from
DARPA to Integrate Multiple Organ-on-Chip Systems to Mimic the Whole Human
Body (July 24, 2012), http://wyss.harvard.edu/viewpressrelease/91/wyss-instituteto-receive-up-to-37-million-from-darpa-to-integrate-multiple-organonchip-systems
-to-mimic-the-whole-human-body (last visited May 2, 2013).
106. Id.
107. National Institutes of Health, Stem Cell Information, http://stemcells.
nih.gov/news/newsArchives/pages/stemfactsheet.aspx (last visited May 3, 2013).
108. Id.
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Center for Regenerative Medicine at The Scripps Research Institute
are building a bank of ethnically diverse induced pluripotent stem
cells to screen for toxicity of drugs that is correlated with ethnic
background.109 The goal of this research is to allow drugs to be tested
on groups of people who are least likely to have adverse side
effects.110
Researchers at the Laboratory for Stem Cells and Tissue Engineering at Columbia University are working to develop a drug development model using pluripotent stem cells to make personalized
models of organs on which to test new drugs.111 These personalized
models seek to improve drug development by replacing traditional
animal testing methods with those that mimic a particular person’s
response.112
Phase 0/Exploratory IND
Phase 0 trials are first-in-human clinical trials that involve limited human exposure, and have no therapeutic intent.113 Phase 0 trials
aim to increase the chance of success of the drug in development114
by providing human pharmacokinetic and pharmacodynamics data
early in the drug development process.115 The goal is to select the
most promising candidate from a set of analogues, and evaluate
human biodistribution, binding, and target effects.116 Phase 0 trials
encourage rational drug development, as drugs unlikely to have a
therapeutic effect can be deprioritised early in the process allowing
for development of more promising and potentially efficacious
agents.117 Only drugs showing sufficient promise in Phase 0 trials
should progress to safety and tolerability evaluation in traditional
Phase 1 trials.118
109. The Scripps Research Institute, The Center for Regenerative Medicine—
Dr. Jeanne Loring, http://www.scripps.edu/loring/research.html (last visited May
2, 2013).
110. Id.
111. TED, Nina Tandon: Could Tissue Engineering Mean Personalized
Medicine?, http://www.ted.com/talks/nina_tandon_could_tissue_engineering_mean
_personalized_medicine.html (last visited May 2, 2013).
112. Id.
113. Kummar, supra note 6, at 742.
114. Id. at 743.
115. Id. at 741.
116. Id. at 742.
117. Id. at 745.
118. Id. at 744.
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Microdosing
Microdosing is a process where researchers administer small
doses of a drug to human volunteers, then use positron emission tomography and accelerator mass spectrometry to assess
pharmacokinetic data.119 Current microdosing involves animal models to determine the starting dose.120 Animal models can be eliminated from microdosing by starting the dosage at 1ng because the
usual starting dose for drugs is between 100ng and 100μg, and 1 ng is
lower than the most toxic substance currently known.121 Although
microdosing is currently used only to test pharmacokinetic data,
microdosing could be used for evaluating other properties such as
toxicity by increasing the dose incrementally.122 This would allow
researchers to determine toxicity early in the drug development process without distraction from animal data.123

Part IV: FDA Effort to Validate More Reliable
Testing Methods
The FDA recognizes it should take an active role in developing
new drug testing methods and validation of these methods.124 The
FDA is involved in the projects discussed below which aim to develop more reliable test methods:
Critical Path Initiative
The FDA began its Critical Path Initiative (CPI) to drive innovation in the scientific processes through which medical products are
developed, evaluated, and manufactured.125 CPI was launched in
2004 with a report that explained the need to reduce time and resources expended on candidate products that are unlikely to succeed,
and the need to make new tools necessary to distinguish earlier in the
process those candidates that hold promise from those that do not.126
As part of the CPI, the FDA issued an exploratory IND guidance,
119. C. RAY GREEK, supra note 21, at 131.
120. Id.
121. Id.
122. Id. at 132.
123. Id.
124. Prater, supra note 15, at slide 14.
125. FDA’s Critical Path Initiative, http://www.fda.gov/ScienceResearch/
SpecialTopics/CriticalPathInitiative/ucm076689.htm (last visited May 3, 2013).
126. U.S. Food and Drug Admin., supra note 2, at i.

\\jciprod01\productn\N\NCP\7-1\ncp112.txt

104

unknown

Seq: 16

BIOTECHNOLOGY & PHARMACEUTICAL LAW REVIEW

15-MAY-14

12:18

[Vol. 7:89

which aimed to expedite the identification and development of promising candidate drugs.127
Advancing Regulatory Science
Regulatory science is the application of science to the development and utilization of new tools, standards, and approaches for the
assessment of product efficacy, safety, and quality.128 In order to
modernize testing and enhance product safety, the FDA recognizes
the need to develop better models of human adverse response that are
not based on animals.129 In 2010, the FDA and NIH formed a joint
leadership council that issues awards to advance regulatory
science.130
Microphysiological Systems Program
The DARPA-FDA-NIH Microphysiological Systems Program
formed in 2011 to support development of human microsystems, or
organ chips, to screen for safe and effective drugs. Microphysiological systems are meant to replace the current preclinical paradigm.131
This program awarded research contracts to The Wyss Institute at
Harvard and Massachusetts Institute of Technology to develop
microphysiological systems.132
Integrated Microphysiological Systems for Drug Efficacy and
Toxicity Testing is another FDA program formed to advance
microphysiological systems.133 This program focuses on the development of physiologically and pathologically accurate human models of
any organ system using tissue-engineering platforms that either already exist or are being developed simultaneously through the
DARPA-FDA-NIH program.134
127. Kummar, supra note 6, at 288.
128. Prater, supra note 15, at slide 3.
129. Suzanne Fitzpatrick, U.S. Food and Drug Admin. Powerpoint
Presentation, FDA/NIH/DARPA Microphysiological Systems Program and
Qualification of Drug Development Tools, slide 5 (2012), www.lorentzcenter.nl/lc/
web/2012/510/. . ./Fitzpatrick.pptx.
130. Id.at slide 6.
131. Id. at slide 8.
132. Id. at slide 7.
133. Prater, supra note 15, at slide 15.
134. Id.
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Stem/Progenitor Cell-Derived Human Micro-Organs and
Micro-Tissues
The focus of this program is development of in vitro multi-cellular models of human physiology that provide advancements over current human stem-cell and progenitor-derived cell type selectivity approaches through improvements in differentiation efficiencies, celltype diversity, genetic complexity, and utilization of 3D culturing approaches to enhance cellular microenvironments.135
Drug Development Tools Qualification Program (DDT)
DDT is a FDA program that provides a mechanism for formal
review by CDER to qualify new tools that would benefit drug development.136 DDT is an example of a new validation strategy involving
fit-for-purpose qualification, but is a complex process that requires
significant time and resources.137
The qualification of a drug development tool begins with a
meeting of CDER personnel and the biomarker sponsors who consult
regarding the information needed to support the application.138 Once
the application is submitted, CDER and other FDA scientists complete a multi-disciplinary formal review of the submission.139 If the
tool is qualified, the decision is publicly communicated through a
FDA guidance document and drug sponsors can submit data obtained
by the validated DDT model.140

Part V: Recommendations for Further FDA Action
The FDA will play a fundamental role in making the goal of
moving drug development into the 21st century a reality because the
FDA regulates and oversees drug development. The need for updated
FDA validation tools, clear regulations and guidance documents
stems from the fact that scientific options exist today, and will continue to emerge, that did not exist when regulations that mandate
animal testing were enacted.141
135.
136.
137.
138.
139.
140.
141.

Id. at slide 17.
Fitzpatrick, supra note 129, at slide 18.
Prater, supra note 15, at slide 21.
Fitzpatrick, supra note 129, at slide 27.
Id.
Id.
C. RAY GREEK, supra note 21, at 131.
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Validation of New Methods
Despite efforts to develop better testing methods, most of the
tools used for toxicology and human safety testing are decades old.142
This is a problem because researchers are using last century’s tools to
evaluate this century’s scientific advances.143 Further, animal models
for testing drug safety and efficacy are presumed valid, while nonanimal methods must be validated.144 Consequently, most animal
model test methods have never been validated,145 while current formal approaches to validation of non-animal methods involve lengthy
processes that require validating the non-animal data against the
animal data.146
The FDA acknowledges a clear need to determine the relevance
of new testing methods to what occurs in humans, rather than what
occurs in test animals.147 This justifies abandoning animal models as
the gold standard for new preclinical methods to be measured
against.148 Applying the animal model one-size fits all approach to
validation is not conducive to incorporating emerging science into
regulatory decision-making framework because the purpose of each
test in the regulatory paradigm must be taken into consideration.149
FDA Regulation
FDA regulations require animal testing as part of the current
drug development paradigm.150 The FDA stated the IND regulation
allows flexibility to accept non-animal models when appropriate.151
Further, the FDA claims information from models validated through
DDT is sufficient without other data.152 However, FDA regulations
142. U.S Food and Drug Admin., at 16.
143. Janet Woodcock & Raymond Woosley, The FDA Critical Path Initiative
and Its Influence on New Drug Development, 59 ANN. R. OF MED. 1, 1 (2008).
144. Prater, supra note 15, at slide 20.
145. Orsolya E. Varga, et al., Validating Animal Models for Preclincial
Research: A Scientific and Ethical Discussion, in 38(3) ALT. LAB. ANIMAL 245
(2010).
146. Prater, supra note 15, at slide 20.
147. Fitzpatrick, supra note 129, at slide 17.
148. Id.
149. Prater, supra note 15, at 4.
150. 21 C.F.R § 312.23(a)5(ii) (West 2012), 21 C.F.R § 312.23(a)(5)(iii)
(West 2012), 21 C.F.R. 312.23(8)(a)(i) (West 2012), 21 C.F.R. § 312.23(8)(a)(ii)
(West 2012), 21. C.F.R. § 312.23 (10)(i) (West 2012).
151. Dorsey, supra note 19, at 2.
152. Fitzpatrick, supra note 129, at slide 28.
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mandate animal data, making this alleged flexibility seem nonexistent.
Researchers who use validated non-animal methods still complete the traditional animal testing in order to comply with FDA regulations and fear of disapproval of their NDA.153 This suggests current
FDA regulations stall the drug development process by dis-incentivizing researchers from using newer validated methods because the
animal data is required and accepted.154 Current regulations that mandate animal data perpetuate the notion that animal models are reliable
for use in human drug development, despite FDA efforts to move
away from animal models. To correct the regulation language, the
FDA would simply need to replace the language calling for animal
testing with language calling for data obtained from a scientifically
validated testing method.
Guidance
The FDA has issued twenty-eight guidance documents regarding
animal testing. In contrast to FDA efforts to develop human-based
methods, none of the guidance documents recommend the use of
non-animal methods. The issued guidance documents, including
those accepted through DDT, either state a specific non-animal model
can be used, or seek to improve upon existing animal models. As part
of the ICH, the FDA tends to accept ICH guidelines. Contrary to the
alleged flexibility of the FDA IND regulation, the ICH has issued
fifteen guidance documents for animal testing and none recommending non-animal models.
The FDA outlined the importance of issuing a clear guidance to
industry and FDA staff that recommends researchers use non-animal
models when validated, adequate, and feasible.155 To date, this guidance has not been issued and is not on the 2014 guidance agenda,
suggesting it is not in the pipeline. If the FDA sincerely wants to
move from animal testing as the gold standard for preclinical studies,
the FDA should issue a general guidance recommending the use of
non-animal testing methods where the method is scientifically validated, adequate and feasible. This would further communicate the
153. Celia Henry Arnaud, In the Search for New Drugs, Diverging Roads For
Microdosing, 91 CHEMICAL AND ENGINEERING NEWS 9 (2013).
154. Id.
155. Dorsey, supra note 19, at 2.
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FDA’s commitment to propel research forward because the recommendation is likely to keep researchers from interpreting the animal
data as necessary.
The FDA should continue to issue specific guidance documents
for each new validated method that becomes available. However, the
guidance document should recommend the use of the validated
method over the animal model, not simply communicate the approval
of the new method, given that the animal model was not validated.

Conclusion
Human drug development costs consistently increase while drug
development success rates remain low, and many uncertainties exist,
including failures in predicting toxicity, safety, and efficacy despite
extensive animal testing.156 While collaboration of all interested parties is important, change must start with the FDA because the FDA is
the ultimate decision-maker in the drug development process. The
FDA acknowledges the need to move away from animal models, but
21st Century emerging methods are tested against animal models,
FDA regulations require animal data, and guidance recommending
new models over animal data is non-existent.
The FDA and industry are working to develop safer and more
effective models, but acceptance of these models is slow, and the
solution to replacing animal models is likely a combination of in vitro, in silico, and microdosing. Once regulations and guidance documents are updated, interested parties may be more inclined to invest
research and development funds into developing testing methods that
are human-based, resulting in safer and more effective drugs. Further,
drug sponsors may be more confident in their decision to use emerging methods because expectations will be clearer.
All emerging testing methods share a similar goal – to replace
traditional animal testing methods that are not sufficiently predictive
of human response, with safer and more effective human-based testing methods. With action and collaboration among all interested parties, drug development will move into the 21st Century and drug testing will produce safer and more effective drugs.
156. Fitzpatrick, supra note 129, at slide 2.

